Myriad Genetics Inc (MYGN)

MYGN (NASDAQ:Diversified Services)
pos +0.00
Today's Range: 0.00 - 0.00 | MYGN Avg Daily Volume: 1,104,000
Last Update: 07/28/14 - 3:59 PM EDT
Volume: 0
YTD Performance: 72.12%
Open: $0.00
Previous Close: $36.11
52 Week Range: $20.02 - $42.50
Oustanding Shares: 74,823,792
Market Cap: 2,769,976,780
6-Month Chart
TheStreet Ratings Grade for MYGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 4 4
Moderate Buy 0 0 0 0
Hold 8 8 9 9
Moderate Sell 0 0 0 0
Strong Sell 2 2 2 2
Mean Rec. 2.71 2.71 2.73 2.73
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 15.69
Price Earnings Comparisons:
MYGN Sector Avg. S&P 500
15.69 15.80 28.94
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-7.48% 14.96% 69.29%
Revenue 23.60 0.69 0.19
Net Income 31.20 -0.03 -0.01
EPS 36.10 0.15 0.05
Earnings for MYGN:
Revenue 0.61B
Average Earnings Estimates
Qtr (06/14) Qtr (09/14) FY (06/14) FY (06/15)
Average Estimate $0.46 $0.48 $2.40 $2.06
Number of Analysts 10 6 11 11
High Estimate $0.52 $0.52 $2.46 $2.40
Low Estimate $0.44 $0.45 $2.38 $1.77
Prior Year $0.53 $0.68 $1.77 $2.40
Growth Rate (Year over Year) -12.83% -28.92% 35.75% -14.19%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Apr 02, 2014 | 8:16 AM EDT
MYGN raised its number, Jefferies said. Driven by unexpected boost to BRCA pricing. $33 price target. 
Feb 07, 2014 | 8:25 AM EST
MYGN was upgraded from Underperform to Neutral, Credit Suisse said. $29 price target. Base business can hold up better than expected an...
Feb 05, 2014 | 7:58 AM EST
MYGN was upgraded from Underperform to Market Perform, JMP Securities said. Company is executing well, despite increased competition.&n...
Dec 30, 2013 | 7:41 AM EST
MYGN was downgraded from Market Perform to Underperform, JMP Securities said. $15 price target. BRCA pricing is lower than expected.&nb...
Dec 03, 2013 | 8:16 AM EST
MYGN was downgraded from Outperform to Market Perform, JMP Securities said. Company could face lower reimbursement levels.
Oct 21, 2013 | 8:02 AM EDT
MYGN was downgraded from Neutral to Underperform, Credit Suisse said. $20 price target. Company is facing increased competition.  ...
Jun 14, 2013 | 8:40 AM EDT
MYGN was downgraded to Market Perform after a mixed ruling on gene patents, said Leerink Swann. With focus turning to cancer testing, s...
Jun 14, 2013 | 8:35 AM EDT
MYGN earnings estimates were lowered on the gene-patent case ruling, Credit Suisse said. SCOTUS upheld cDNA's patent eligibility, yet c...
May 31, 2013 | 7:08 AM EDT
MYGN was downgraded from Buy to Hold, Jefferies said. $31 price target. Stock is up moer than 20%, ahead of the pending Supreme Court d...

Earnings Roundup Real Money Pro($)

Here is my compilation of last night's profit reports.

Columnist Conversations

I am still watching MON for a possible reversal against the time/price parameters. So far we are not seeing a...
Market stages nice comeback from early losses to end basically flat. Gilead Sciences (GILD)has a nice day post...
Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...
Going to $47 without Otis...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.